Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer (BMC Cancer (2019) 19 (517) DOI: 10.1186/s12885-019-5687-0)

1Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Following publication of the original article [1], the authors reported the following errors in the article. 1) In Table 2, the layout has been updated. The corrected Table 2 is supplied below: 2) The legend for Fig. 3 has been adapted for clearer readability. The updated legend is as follows: 3) The competing interests statement has been updated below..

Cite

CITATION STYLE

APA

Perez, E. A., De Haas, S. L., Eiermann, W., Barrios, C. H., Toi, M., Im, Y. H., … Ellis, P. A. (2019, June 24). Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer (BMC Cancer (2019) 19 (517) DOI: 10.1186/s12885-019-5687-0). BMC Cancer. BioMed Central Ltd. https://doi.org/10.1186/s12885-019-5831-x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free